Vivek Subbiah: Excited to join as a panelist in the upcoming STAT statnews event “Cancer’s Breakthrough Engine”

Vivek Subbiah shared a post on LinkedIn:

“Save the Date! Excited to join as a panelist in the upcoming STAT statnews
event “Cancer’s Breakthrough Engine” moderated by the amazing Adam Feuerstein

When: Tuesday, December 19, 2023, 12:00 p.m. – 1:00 p.m. CST
alongside, American Association for Cancer Research President elect Dr. Patricia Lorusso, & Cancer Journal Editor-in-chief Suresh S. Ramalingam, MD

Join us as we dive into the world of Precision Medicine discussing successes, challenges, and cutting-edge approaches in precision cancer medicines, from TKI’s, IO, ADC’s and beyond”

For the registration click here.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the  Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.